Arch Gerontol Geriatr
Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Published: March 2025
Background: This study aims to assess the cost-effectiveness of percutaneous endoscopic gastrostomy (PEG) and nasogastric tube (NGT) in older adults with advanced dementia, compared with non-artificial nutrition.
Methods: Retrospective cohort study. Medical claims data and long-term care claims data from Fukuoka Prefecture, Japan, were used. We identified 3,882 older adults (≥75 years) with advanced dementia who were hospitalized between April 2016 and March 2019 due to dysphagia, malnutrition, or aspiration pneumonia. Using propensity score matching, we matched 192 patients in the PEG group with 192 in the non-artificial nutrition group, and 490 patients in the NGT group with 490 in the non-artificial nutrition group. We examined the survival years and total costs of each patient from the date of admission to March 31, 2020, and thereby estimated the cost-effectiveness of PEG and NGT, respectively, versus non-artificial nutrition. The net benefit regression model was employed to estimate the incremental net benefits (INB) with varying values of willingness-to-pay (WTP) for PEG and NGT. Furthermore, cost-effectiveness acceptability curve was used to present the probability of the cost-effectiveness of each intervention.
Results: As WTP increased from JPY 7,747,909 (equivalent to US$51,546) to JPY 28,163,651 (equivalent to US$187,371), the probability of PEG being cost-effective increased from 50 % to nearly100 %. The NGT group had negative INB estimates.
Conclusions: Both PEG and NGT are less likely to provide economic values for patients with advanced dementia. However, this conclusion should be further refined through detailed cost-effectiveness analysis from multiple perspectives.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.archger.2025.105812 | DOI Listing |
Alzheimers Dement (Amst)
March 2025
Introduction: Knowledge gaps remain about the prognosis of mild cognitive impairment (MCI). Conversion rates to dementia vary widely, and reversion to normal cognition has gained attention. This review updates evidence on MCI conversion risk and probability of stability and reversion.
View Article and Find Full Text PDFInt J Mol Sci
February 2025
Unit of Medical and Dental Sciences, Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.
Prion diseases are fatal neurological disorders characterized by abnormal protein accumulation in the brain, leading to neurodegeneration, dementia, and ataxia. Sporadic Creutzfeldt-Jakob disease (sCJD), the most common form, accounts for 80-90% of cases and progresses rapidly, with most patients surviving <6 months to a year after symptom onset, indicating the importance of early diagnosis. The disease is classified into six subtypes based on PRNP gene polymorphisms, with differences in protein degradation patterns contributing to the diversity of clinical symptoms.
View Article and Find Full Text PDFInt J Mol Sci
February 2025
Department of Computer Engineering, Faculty of Computer and Informatics Engineering, Istanbul Technical University, Istanbul 34467, Türkiye.
There is still a lack of effective therapies for Alzheimer's disease (AD), the leading cause of dementia and cognitive decline. Identifying reliable biomarkers and therapeutic targets is crucial for advancing AD research. In this study, we developed an aggregative multi-filter gene selection approach to identify AD biomarkers.
View Article and Find Full Text PDFDiagnostics (Basel)
March 2025
Tabriz USERN Office, Universal Scientific Education and Research Network (USERN), Tabriz 5164736931, Iran.
Alzheimer's disease (AD) remains a significant global health challenge, affecting millions worldwide and imposing substantial burdens on healthcare systems. Advances in artificial intelligence (AI), particularly in deep learning and machine learning, have revolutionized neuroimaging-based AD diagnosis. However, the complexity and lack of interpretability of these models limit their clinical applicability.
View Article and Find Full Text PDFCNS Neurosci Ther
March 2025
State Key Laboratory of Biomedical Imaging Science and System, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.
Aims: Alzheimer's disease (AD) involves a prolonged presymptomatic or preclinical stage with subtle pathological changes. Apolipoprotein E4 (APOE4) is a significant genetic risk factor for AD, yet its specific role at the presymptomatic stage is not fully understood. This study aimed to elucidate the cellular and molecular effects of APOE4 compared to APOE3 on AD progression during the presymptomatic stage.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.